Rachel Narozniak, MA

Articles

Tucatinib Approval Adds Impact to HER2+ Breast Cancer Paradigm

May 15th 2020

Therapeutic options for pretreated HER2-positive breast cancer now include tucatinib (Tukysa) as part of a triplet regimen with a tolerable safety profile that promises improved quality of life.

Chasing a Cure for GBM: Investigators Test Multiple Regimens in Novel Trial

May 14th 2020

Investigators of the first global adaptive phase 2/3 GBM Adaptive Global Innovative Learning Environment platform trial are implementing a multiarm, 2-stage approach to concurrently evaluate single-agent and combination regimens in glioblastoma.

Chasing a Cure for GBM: Investigators Test Multiple Regimens in Novel Trial

May 14th 2020

AI System Helps Guide Care for High-Risk Patients in Oncology

May 6th 2020

In an era of value-based care, the ability to triage the needs of patients with cancer who are most likely to experience significant difficulties is becoming a priority for community oncology practices and hospital systems.

Breast Cancer Guidelines Carve Out Category for Low ER Expression

May 4th 2020

The American Society of Clinical Oncology and College of American Pathologists have further refined their recommendations for estrogen receptor and progesterone receptor testing protocols in patients with breast cancer.

Investigators Seek to Supplant Oropharyngeal SOC With Proton Therapy

April 30th 2020

Hoping to minimize the off-target effects associated with radiation in patients with oropharyngeal cancer, investigators are testing the hypothesis that intensitymodulated proton therapy can deliver doses as effectively as the current standard of care with less damage to surrounding tissue.

No COVID-19 Detour for Global Hematology Therapies

April 29th 2020

With travel restrictions and reduced transportation options, the global spread of coronavirus disease 2019 has disrupted international networks that supply patients with biological materials needed for sophisticated hematologic therapies.

Clinical Factors Predict Deterioration Among Patients With Cancer, COVID-19

April 29th 2020

ECOG performance status, cancer type, and type of prior therapy received can predict risk for clinical worsening or death in patients with cancer who contract the coronavirus disease 2019.

Study Tests Novel Doublet Designed to Promote Immunity in cSCC

April 13th 2020

Investigators are testing the hypothesis that administering cetuximab with an anti–PD-L1 agent will induce immunostimulatory synergy and prolong survival in patients with cutaneous squamous cell carcinoma.

Application of Neratinib in Breast Cancer Broadens

April 9th 2020

Adam M. Brufsky, MD, PhD, FACP, discusses the use of neratinib and the importance of expanding the treatment portfolio in HER2-positive metastatic breast cancer.

At the Epicenter: How SCCA Braced Itself for COVID-19

April 8th 2020

When the first case of coronavirus disease 2019 was diagnosed in Washington on January 20, 2020 clinicians at Seattle Cancer Care Alliance decided to act expeditiously and unhesitatingly to minimize disease spread.

Cancer Centers Go On the Offensive to Reduce COVID-19 Risk

April 2nd 2020

From implementing telemedical approaches to resequencing treatments, cancer centers across the nation have nimbly adapted to face the clinical challenges posed by the novel coronavirus 2019 disease.

Investigators Seek to Improve SOC in Cervical Cancer

April 1st 2020

Motivated to move the needle in cervical cancer, investigators are adding durvalumab to standard-of-care concurrent chemoradiation therapy and brachytherapy to determine whether PD-L1 blockade is a key to improving survival outcomes.

Isatuximab Affords the R/R Multiple Myeloma Setting a Tolerable New Alternative

March 31st 2020

Ken Shain, MD, PhD, discusses isatuximab-irfc and its potential to move into different stages of the multiple myeloma paradigm following further clinical investigation.

COVID-19 Is "Biggest Medical Issue" of Modern Times, Rugo Says

March 20th 2020

The need to establish preventive procedures that keep pace with the rapid evolution of coronavirus 2019 presents numerous challenges for the oncology field as institutions adapt standard treatment protocols to minimize the risk for virus spread among clinicians and patients alike.

Investigators Pursue Less-Toxic Treatment in Frontline CLL

March 16th 2020

Investigators are evaluating whether the addition of venetoclax to a standard doublet regimen in chronic lymphocytic leukemia can induce responses deep enough to allow patients to not only suspend long-term treatment but also avoid associated toxicity.

Avapritinib Is a Game Changer for PDGFRA Exon 18-Mutated GIST

March 14th 2020

Michael C. Heinrich, MD, discusses the recent approval of avapritinib for advanced PDGFRA exon 18–mutated gastrointestinal stromal tumor.

Further Study Is Needed to Maximize Therapeutic Benefit in Urothelial Cancer

March 13th 2020

In metastatic urothelial cancer, the portfolio of immunologic therapies is robust, but the treatment paradigm for these agents requires refinement.

Updated Guideline Moves Genetic Testing Beyond BRCA

March 13th 2020

Driven by advances in genetic testing methods and the discovery of actionable mutations beyond BRCA, an update to the National Comprehensive Cancer Network’s Guidelines for genetic testing in breast, ovarian, and pancreatic cancers encompasses a much broader range of genes that predict risk for disease occurrence.

Coronavirus: What Oncologists Are Telling Their Patients

March 9th 2020

Patient concern about coronavirus 2019 varies by oncology clinic according to the OncologyLive® advisory board members, who discussed in a recent interview how COVID-19 has guided their patient interactions and what steps they are advising patients to take to protect themselves.